Effects of carbamazepine and valproate on immunological assessment in young epileptic patients

Area of Science:

• Immunology
• Neurology
• Pharmacology

Background:

• Epilepsy is a neurological disorder affecting millions globally.
• Anticonvulsant medications are standard treatments for epilepsy.
• The impact of these drugs on the immune system, particularly in children, requires further investigation.

Purpose of the Study:

• To investigate the effects of carbamazepine (CBZ) and sodium valproate (VPA) on serum immunoglobulin levels and peripheral blood lymphocyte subsets in epileptic children.
• To compare immune parameters between treated epileptic children, untreated epileptic children, and healthy controls.

Main Methods:

• Quantitative analysis of serum immunoglobulin A (IgA), immunoglobulin G (IgG), and immunoglobulin M (IgM) levels.
• Flow cytometry assessment of peripheral blood lymphocyte subsets, including OKT8.
• Comparative statistical analysis between three groups: CBZ/VPA-treated epileptic children, untreated epileptic children, and healthy controls.

Main Results:

• No significant differences were observed in mean IgA, IgG, IgM, or lymphocyte subsets between treated, untreated, and control groups.
• Patients on carbamazepine showed a trend towards lower serum IgG concentrations compared to untreated patients and those on valproate.
• The OKT8 subset was significantly higher in generalized epilepsy than partial epilepsy, potentially linked to antiepileptic treatment.

Conclusions:

• Current anticonvulsant therapies (CBZ, VPA) do not appear to cause major alterations in the immune status of epileptic children.
• Observed immune variations are unlikely to be solely attributed to the clinical type of epilepsy or the specific drugs used.